Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-Current Deferred Tax Liability (2023 - 2025)

Barinthus Biotherapeutics' Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at $254000.0 for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 42.01% year-over-year to $254000.0; the TTM value through Dec 2025 reached $254000.0, down 42.01%, while the annual FY2025 figure was $254000.0, 42.01% down from the prior year.
  • Non-Current Deferred Tax Liability reached $254000.0 in Q4 2025 per BRNS's latest filing, down from $320000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $11.8 million in Q4 2023 to a low of $254000.0 in Q4 2025.
  • Average Non-Current Deferred Tax Liability over 3 years is $2.0 million, with a median of $416000.0 recorded in 2025.
  • Peak YoY movement for Non-Current Deferred Tax Liability: plummeted 96.27% in 2024, then decreased 29.98% in 2025.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $11.8 million in 2023, then tumbled by 96.27% to $438000.0 in 2024, then crashed by 42.01% to $254000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Non-Current Deferred Tax Liability are $254000.0 (Q4 2025), $320000.0 (Q3 2025), and $391000.0 (Q2 2025).